128 related articles for article (PubMed ID: 38634742)
1. Predominant CD8
Tominaga K; Toda E; Takeuchi K; Takakuma S; Sakamoto E; Kuno H; Kajimoto Y; Terasaki Y; Kunugi S; Mii A; Sakai Y; Terasaki M; Shimizu A
Pathol Int; 2024 Apr; ():. PubMed ID: 38634742
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
3. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
[TBL] [Abstract][Full Text] [Related]
4. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract][Full Text] [Related]
5. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
6. Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor-Induced Kidney Injury.
Abudayyeh A; Suo L; Lin H; Mamlouk O; Abdel-Wahab N; Tchakarov A
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358686
[TBL] [Abstract][Full Text] [Related]
7. Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?
Draibe JB; García-Carro C; Martinez-Valenzuela L; Agraz I; Fulladosa X; Bolufer M; Tango A; Torras J; Soler MJ
Clin Kidney J; 2021 Mar; 14(3):884-890. PubMed ID: 33777371
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
Moturi K; Sharma H; Hashemi-Sadraei N
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
[TBL] [Abstract][Full Text] [Related]
9. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
11. Association of Baseline Tumor-Specific Neoantigens and CD8
Kerepesi C; Abushukair HM; Ricciuti B; Nassar AH; Adib E; Alessi JV; Pecci F; Rakaee M; Fadlullah MZH; Tőkés AM; Rodig SJ; Awad MM; Tan AC; Bakacs T; Naqash AR
JCO Precis Oncol; 2024 Feb; 8():e2300439. PubMed ID: 38330262
[TBL] [Abstract][Full Text] [Related]
12. Glutamyl-prolyl-tRNA synthetase (EPRS1) drives tubulointerstitial nephritis-induced fibrosis by enhancing T cell proliferation and activity.
Kang C; Yun D; Yoon H; Hong M; Hwang J; Shin HM; Park S; Cheon S; Han D; Moon KC; Kim HY; Choi EY; Lee EY; Kim MH; Jeong CW; Kwak C; Kim DK; Oh KH; Joo KW; Lee DS; Kim YS; Han SS
Kidney Int; 2024 May; 105(5):997-1019. PubMed ID: 38320721
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
Front Immunol; 2022; 13():912180. PubMed ID: 35844502
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis.
Mizushima I; Yamada K; Fujii H; Inoue D; Umehara H; Yamagishi M; Yamaguchi Y; Nagata M; Matsumura M; Kawano M
Mod Rheumatol; 2012 Nov; 22(6):859-70. PubMed ID: 22262474
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
18. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
[TBL] [Abstract][Full Text] [Related]
19. Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis: distinction from non-IgG4-related tubulointerstitial nephritis.
Yoshita K; Kawano M; Mizushima I; Hara S; Ito Y; Imai N; Ueno M; Nishi S; Nomura H; Narita I; Saeki T
Nephrol Dial Transplant; 2012 Jul; 27(7):2755-61. PubMed ID: 22228836
[TBL] [Abstract][Full Text] [Related]
20. Distinct immune-effector and metabolic profile of CD8
Benesova K; Kraus FV; Carvalho RA; Lorenz H; Hörth CH; Günther J; Klika KD; Graf J; Diekmann L; Schank T; Christopoulos P; Hassel JC; Lorenz HM; Souto-Carneiro M
Ann Rheum Dis; 2022 Aug; 81(12):1730-41. PubMed ID: 35922125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
